Abstract: Objective〖HTSS〗To analyze the effects of holmium laser resection of bladder tumors(HOLBT) combined with gemcitabine bladder perfusion therapy on patients with superficial bladder cancer and its affection on levels of serum CXCL5 and value of urinary NMP 22.
〖WTHZ〗Methods〖HTSS〗A total of 104 patients with csuperficial bladder cancer treated were selected as research objects, and divided into control group and observation group(52 cases in each group). Control group was given HOLBT, and observation group was treated with gemcitabine bladder perfusion therapy on the basis of control group. The postoperative recurrence, average recurrence time, average survival time and serum levels of growth factor, level of CXCL5 and NMP22 were compared between two groups.
〖WTHZ〗Results〖HTSS〗The postoperative recurrence within 1 year and 3 years and the average recurrence time and average survival time in control group after treatment were significantly higher than those in observation group, the difference was statistically significant(P＜0.05 or P＜0.01). The serum VEGF, aFGF, bFGF, CXCL5 and urinary NMP22 levels in observation group were significantly lower than those in control group. After treatment, the levels of VEGF, α FGF, β FGF, CXCL5 and NMP22 in the two groups were lower than those before treatment（P＜0.01）.
〖WTHZ〗Conclusion〖HTSS〗The HOLBT combined with gemcitabine bladder perfusion therapy on patients with superficial bladder cancer, can effectively reduce postoperative recurrence, prolong the mean survival time of patients, and can significantly reduce the level of CXCL5 and NMP22.